Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDNewAmsterdam Pharma Company NV Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 9 | -$0.58 | -$0.35 | -$0.46 |
| Q2 2026 | 8 | -$0.54 | -$0.36 | -$0.48 |
| Q3 2026 | 8 | -$0.57 | -$0.34 | -$0.48 |
| Q4 2026 | 6 | -$0.70 | -$0.20 | -$0.45 |
| Q1 2027 | 3 | -$0.87 | -$0.24 | -$0.55 |
| Q2 2027 | 5 | -$0.90 | -$0.25 | -$0.57 |
| Q3 2027 | 3 | -$0.54 | -$0.15 | -$0.34 |
| Q4 2027 | 6 | $0.02 | $0.07 | $0.04 |
| Q1 2028 | 4 | -$0.93 | -$0.26 | -$0.59 |
| Q2 2028 | 6 | -$0.88 | -$0.25 | -$0.56 |
| Q3 2028 | 4 | -$0.85 | -$0.24 | -$0.54 |
| Q4 2028 | 7 | -$0.74 | -$0.21 | -$0.47 |
NewAmsterdam Pharma Company NV Earnings Date And Information
NewAmsterdam Pharma Company NV last posted its earnings results on Thursday, May 7th, 2026. The company reported $-0.4 earnings per share for the quarter, topping analysts' consensus estimates of $-0.46 by $0.06. The company had revenue of 3.04 M for the quarter and had revenue of 22.50 M for the year. NewAmsterdam Pharma Company NV has generated $-2 earnings per share over the last year ($-1.75 diluted earnings per share) and currently has a price-to-earnings ratio of -17.03. NewAmsterdam Pharma Company NV has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
NewAmsterdam Pharma Company NV Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/07/2026 | Q1 2026 | -$0.46 | -$0.40 | 0.06 | $1.74 M | $3.04 M |
| 02/18/2026 | Q4 2025 | -$0.43 | -$0.65 | -0.22 | $2.88 M | $32.00 K |
| 11/05/2025 | Q3 2025 | -$0.38 | -$0.61 | -0.23 | $5.31 M | $348.00 K |
| 08/06/2025 | Q2 2025 | -$0.52 | -$0.15 | 0.37 | $3.49 M | $19.15 M |
| 05/08/2025 | Q1 2025 | -$0.45 | -$0.34 | 0.11 | $1.56 M | $2.98 M |
| 02/26/2025 | Q4 2024 | -$0.48 | -$0.98 | -0.5 | $1.76 M | $12.77 M |
| 11/06/2024 | Q3 2024 | -$0.48 | -$0.18 | 0.3 | $1.87 M | $29.11 M |
| 08/07/2024 | Q2 2024 | -$0.59 | -$0.41 | 0.18 | $1.21 M | $2.28 M |
| 05/08/2024 | Q1 2024 | -$0.54 | -$1.06 | -0.52 | $1.62 M | $1.40 M |
| 02/28/2024 | Q4 2023 | -$0.55 | -$0.52 | 0.03 | N/A | $803.00 K |
| 09/29/2023 | Q3 2023 | N/A | -$0.56 | N/A | N/A | $2.94 M |
| 08/07/2023 | Q2 2023 | -$0.39 | -$0.43 | -0.04 | N/A | $1.72 M |
| 08/07/2023 | Q1 2023 | -$0.39 | -$0.47 | -0.08 | N/A | $8.63 M |
| 03/31/2023 | Q4 2022 | -$0.61 | -$2.20 | -1.59 | N/A | $5.50 M |
| 11/28/2022 | Q3 2022 | N/A | -$23.19 | N/A | N/A | $5.50 M |
| 06/29/2022 | Q2 2022 | N/A | $0.75 | N/A | N/A | $48.98 M |
| 03/29/2022 | Q1 2022 | N/A | $0.75 | N/A | N/A | $51.72 M |
| 12/30/2021 | Q4 2021 | N/A | -$1.73 | N/A | N/A | $0 |
| 09/29/2021 | Q3 2021 | N/A | -$0.82 | N/A | N/A | $0 |
| 06/29/2021 | Q2 2021 | N/A | -$0.43 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
NewAmsterdam Pharma Company NV Earnings: FAQ's
In the previous quarter, NewAmsterdam Pharma Company NV (:NAMS) reported $-0.4 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.46 by $0.06.
The conference call for NewAmsterdam Pharma Company NV's latest earnings report can be listened to online.
The conference call transcript for NewAmsterdam Pharma Company NV's latest earnings report can be read online.
NewAmsterdam Pharma Company NV (:NAMS) has a recorded annual revenue of $22.50 M.
NewAmsterdam Pharma Company NV (:NAMS) has a recorded net income of $-203,819,000.NewAmsterdam Pharma Company NV has generated $-1.75 earnings per share over the last four quarters.
NewAmsterdam Pharma Company NV (:NAMS) has a price-to-earnings ratio of -17.03 and price/earnings-to-growth ratio is 2.84.